MAGE-A2 was shown to strongly down regulate p53 transactivation function, and association between MAGE-A expression levels and resistance to etoposide treatment was shown in short- term melanoma cell lines harboring wild-type p53[31]. This evidence concerns the gene MAGEA2 and melanoma.